secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surgery Partners, Inc. (SGRY)
CIK:        0001638833
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001638833-22-000002
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surgery Partners reaffirms 2021/2022 guidance, appoints David Doherty as CFO
----------------------------------------------------------------------------

- David Doherty appointed EVP & CFO effective Feb 1, 2022, succeeding Thomas Cowhey who resigns Jan 31, 2022.
- Doherty receives $515K base salary, 75% target bonus, $200K restricted stock award, $800K annual equity target.
- Company reaffirms 2021 Adjusted EBITDA guidance of $325M-$330M and revenue growth 19%-21% vs 2020.
- Completed $185M in three December 2021 acquisitions at ~8.5x 2022E EBITDA; reaffirms 2022 Adj EBITDA min $370M.
- Cowhey to remain through Feb 2022; his unvested PSUs and restricted stock vest in March 2022 as agreed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/0001638833-22-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/sgry-20220105.htm
  HTML page:      https://secwatch.observer/filing/0001638833-22-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer